

Challenges in HCV therapy in the era of DAAs:

Real life experience

Day (1): Wednesday, September 6 th , 2017		
8:30-8:45	Opening Ceremony	
8:45-11:00 am	Session 1 Epidemiology and history of HCV Chairpersons: Prof. Masao Omata, Prof. Abueldahab Elsahly, Prof. Ali Moenis, Prof. Ayman Yousry, Dr. Abdel-Hamid Serwah	
8:45-9:00 am	The end of the HCV night mare 2020-2030	Prof. Alaa Ibrahim
9:00-9.15 am	Worldwide epidemiology and mode of transmission	Prof. Wasim Jafri
9.15-9.30 am	Natural history of HCV before and after DAAs	Prof. Masao Omata
9.30-9.50 am	HCV life cycle and Its impact on the development of DAAs	Dr. Shiv Kumar Sarin
9.50-10.10 am	HCV diagnosis in the era of DAAs and its impact on HCV management	Prof. Tarek Hassanain
10.10-10.50 am	Debate Resistance testing: when and in whom?	
10.10-10.25 am	Baseline resistance testing is clinically relevant and should be routinely analyzed	Prof. Salimur Rahman
10.25-10.40 am	Baseline resistance testing is not clinically relevant except in certain patients and should not be routinely analyzed	Dr. Shiv Kumar Sarin
10.40-10.50 am	Moderators wrap-up and audience vote	
11.10-11.30 am	Break	
11.30-12.30 am	Open Discussion	
12.30-2.30 pm	Session 2 Hepatitis C therapy: New and existing DAAs Chairpersons: Prof. Diana Alcantara-Payawal, Prof. Mohsen Salama, Prof. Omar Haikal, Prof. Mazen Naga, Prof Salem Awadh	
12.30-12.45 pm	Goals of antiviral therapy and long term benefits of SVR	Prof. Masao Omata
12.45-1.10 pm	DAAs and their target: (Classes, combinations, regimens)	Prof. Tarek Hassanain
1.10-1.35 pm	Treatment of HCV G1: Real life experience	Dr. Abdel-Hamid Serwah
1.35-1.50 pm	Treatment of G2 & G3: Real life experience	Prof. Saeed Hamid
1.50-2.05 pm	Treatment of G4: Real life experience	Prof Gamal Shiha
2.05-2.20 pm	Treatment of G5 and 6: Real life experience	Prof. Mindie Nguyen
2.20-2.30 pm	Moderators conclusion and audience comments	
2.30-3.30 pm	Open Discussion	
	Lunch	

Day (2): Thursday, September 7th, 2017

9:00-11:00 am	Session 1 The challenging HCV patient Chairpersons: Prof. Imam Waked, Prof. Gamal Esmat, Prof. Wahed Doss, Prof. Ashraf Omar, Prof. Esmat Shiba, Prof. Manal H El-Sayed	
9:00-9.15 am	Safety and efficacy of DAAs in decompensated cirrhosis	Prof. Mohamed Sharaf Eldin
9.15-9.30am	Patients with renal failure: When and how to treat?	Prof. Necati Ormeci
9.30-9.45 am	Optimal timing of HCV therapy for patients on liver transplant waiting list	Prof. George Lau
9.45-10.05 am	Patients with co-infection: HCV/HBV and HCV/HIV	Prof. Chen-Hua Liu
10.05-10.20 am	Chronic HCV in children: does it make a difference?	Dr. Sadhna Lal
10.20-10.50	Debate: Acute Hepatitis C: Wait or medicate?	
10.20-10.35 am	Wait	Prof. Mamdouh Gabr
10.35-10.50 am	Medicate	Prof. Zaigham Abbas
10.50-11:00 am	Conclusion and audience comments	
11:00-11.30 am	Break	
11.30-12.30 am	Open Discussion	
12.30-2.30 pm	Session 2 The emerging obstacles in HCV therapy: How could we move forward? Chariperson: Prof. Sharma , Prof. Mohamed Elateek, Prof. Hosny Salama, Prof. Yosry Taher, Prof. Taher Elzanaty, Prof. Salem Awadh	
12.30-12.45 pm	Management of DAAs failure and relapses: What's the first line, and what else is available?	Dr Ashish Kumar
12.45-1:00 pm	Effectiveness of DAAs in HCV patients with HCC: Who is likely to get benefit?	Prof. Mamun Al Mahtab
1:00-1.30 pm	Debate: Incidence and pattern of "denovo" HCC in HCV-treated patients with oral DAAs: Do we know enough?	
1:00-1.05 pm	Initial comments	
1.05-1.15 pm	There is increased incidence of "denovo" HCC in HCV patients treated with oral DAAs: Pro	Prof. Yogesh Chawla
1.15-1.25 pm	There is increased incidence of "denovo" HCC in HCV patients treated with oral DAAs: Contra	Mamdouh Gabr
1.25-1.30 pm	Moderators wrap-up and audience vote	
1.30-2.05 pm	Debate: Can we afford to treat all HCV patients or prioritization is needed?	
1.30-1.45 pm	Prioritization is needed and reasonable	Prof. Saeed Hamid
1.45-2:00 pm	All HCV patients should receive antiviral therapy	Prof. Tarek Hassanain
2:00-2.05 pm	Moderators wrap-up and audience vote	
2.05-2.20 pm	Treatment duration: How short can it be?	Prof. Tarek Hassanain
2.20-2.35 pm	Antiviral resistance: Who needs to be tested, when and why?	Prof. Salimur Rahman
2.35-2.40 pm	Q&A	
2.40-3.40 pm	Open Discussion	
Lunch		

Day (3): Friday, September 8th, 2017

9:00-11:00 am	Session 1 Management of HCV-related complications in the era of DAAs Chairpersons: Dr Sadhna Lal, Prof. Serag Zakaria, Prof. Mohamed Sharaf Eldin, Prof. Yehia Elshazly, Prof. Sherif Abdelftah, Prof. Hany Khattab	
9:00-9.15 am	HCV-related lymphoma: a case-based presentation	Prof. A Kadir Dokmeci
9.15-9.30 am	Mixed cryoglobulinaemia: Diagnostic approach and case presentation	Prof. Manoj Kumar
9.30-9.45 am	Adverse events of different combinations of DAAs: What can we do?	Prof. Jose Sollano
9.45-10:00 am	Residual fibrosis after successful anti-HCV therapy: What are the optimal tests?	Hasmik Ghazinian
10:00-10.25 am	Debate	
10:00-10.20 am	Liver fibrosis regression after successful HCV therapy, A Debate	Prof. Aly Elsayed
10.20-10.25 am	Moderators wrap-up and audience vote	
10.25-10.40 am	Liver nodules immediately before, during and immediately after antiviral therapy with DAAs: Where are we going?	Prof. Yogesh Chawla
10.40-11:00 am	Impact of DAAs therapy on portal pressure and haemodynamics in cirrhotic HCV patients	Prof. Barjesh Sharma
11:00-11.15	Conclusion and audience comments	
Gomaa Prayer		
1:00-2:00 pm	Open Discussion	
2:00-4:00 pm	Session 2 Clinical hot points in chronic HCV Chairpersons: Prof. Masao Omata, Prof. Ziad Sharayha, Prof. Helmy Abaza, Prof. Ali Farag, Prof. Hisham Elkhyat	
2:00-2.15 pm	Indeterminate genotypes and therapy	Prof. Seng Gee Lim
2.15-2.30 pm	Surveillance of HCC before and after DAAs therapy: What the clinicians need to know?	Prof. Diana Alcantara-Payawal
2:30-2:40 pm	Treating HCV in CDK	Prof. Aly Elsayed
2.40-4:00 pm	Management of HCV related HCC	
2:40-2:55 pm	HCV and its relation to HCC	Prof. Ashraf Omar
2.55-3:10 pm	Could it be a preventable disease?	Prof. Mamdouh Gabr
3:10-3.25 pm	Combined locoregional therapy	Prof. Talal Amer
3.25-3.40 pm	New drugs	Rosmawati Mohamed
3.40-3.55 pm	Surgery and/or transplantation	Prof. Jody Olson
	Conclusion and audience comments	
3.55-4:00 pm	Closing remarks	